Aimmune’s peanut allergy med Palforzia wins EU approval
Drug becomes first treatment for peanut allergy in the EU
Read More
Tag: Palforzia
Aimmune’s peanut allergy med moves toward EU approval
CHMP grants Palforzia a positive opinion for the treatment of peanut allergic patients
Read More
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
- Gedeon Richter UK takes over UK rights to cariprazine
- Otsuka Pharmaceutical’s Dawnzera receives EC approval for hereditary angioedema prevention
